Literature DB >> 1451236

Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.

S Urba1, J Doroshow, C Cripps, F Robert, E Velez-Garcia, B Dallaire, D Adams, R Carlson, A Grillo-Lopez, J Gyves.   

Abstract

A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4 toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response. We conclude that brequinar given at this dose and on this schedule has no significant activity in advanced squamous-cell carcinoma of the head and neck.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1451236     DOI： 10.1007/bf00685106

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  8 in total

1.  Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).

Authors:  D A Noe; E K Rowinsky; H S Shen; B V Clarke; L B Grochow; W B McGuire; A Hantel; D B Adams; M D Abeloff; D S Ettinger
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

2.  Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.

Authors:  S F Chen; R L Ruben; D L Dexter
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

3.  DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.

Authors:  G Schwartsmann; G J Peters; E Laurensse; F C de Waal; A H Loonen; A Leyva; H M Pinedo
Journal:  Biochem Pharmacol       Date:  1988-09-01       Impact factor: 5.858

4.  A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.

Authors:  E Bork; S Vest; H H Hansen
Journal:  Eur J Cancer Clin Oncol       Date:  1989-10

5.  Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.

Authors:  D L Dexter; D P Hesson; R J Ardecky; G V Rao; D L Tippett; B A Dusak; K D Paull; J Plowman; B M DeLarco; V L Narayanan
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

6.  Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.

Authors:  G Schwartsmann; P Dodion; J B Vermorken; W W ten Bokkel Huinink; J Joggi; B Winograd; H Gall; G Simonetti; W J van der Vijgh; M B van Hennik
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).

Authors:  C L Arteaga; T D Brown; J G Kuhn; H S Shen; T J O'Rourke; K Beougher; H J Brentzel; D D Von Hoff; G R Weiss
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

8.  Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.

Authors:  G Schwartsmann; E Bork; J B Vermorken; C Nieboer; P Dodion; W W ten Bokkel Huinink; C A Seldenrijk; J P Armand; H M Pinedo
Journal:  Cancer       Date:  1989-01-15       Impact factor: 6.860
  8 in total
  10 in total

1.  The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.

Authors:  David B Sykes
Journal:  Expert Opin Ther Targets       Date:  2018-10-17       Impact factor: 6.902

2.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

Review 3.  Brequinar sodium.

Authors:  D V Cramer
Journal:  Pediatr Nephrol       Date:  1995       Impact factor: 3.714

4.  Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

Authors:  H A Burris; E Raymond; A Awada; J G Kuhn; T J O'Rourke; J Brentzel; W Lynch; S Y King; T D Brown; D D Von Hoff
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 5.  DHODH and cancer: promising prospects to be explored.

Authors:  Yue Zhou; Lei Tao; Xia Zhou; Zeping Zuo; Jin Gong; Xiaocong Liu; Yang Zhou; Chunqi Liu; Na Sang; Huan Liu; Jiao Zou; Kun Gou; Xiaowei Yang; Yinglan Zhao
Journal:  Cancer Metab       Date:  2021-05-10

Review 6.  Oncology Therapeutics Targeting the Metabolism of Amino Acids.

Authors:  Nefertiti Muhammad; Hyun Min Lee; Jiyeon Kim
Journal:  Cells       Date:  2020-08-15       Impact factor: 6.600

Review 7.  Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.

Authors:  Melanie Walter; Patrick Herr
Journal:  Cells       Date:  2022-02-20       Impact factor: 6.600

8.  Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.

Authors:  Arthur Branstrom; Liangxian Cao; Bansri Furia; Christopher Trotta; Marianne Santaguida; Jason D Graci; Joseph M Colacino; Balmiki Ray; Wencheng Li; Josephine Sheedy; Anna Mollin; Shirley Yeh; Ronald Kong; Richard Sheridan; John D Baird; Kylie O'Keefe; Robert Spiegel; Elizabeth Goodwin; Suzanne Keating; Marla Weetall
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

9.  Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.

Authors:  Joseph T Madak; Christine R Cuthbertson; Yoshinari Miyata; Shuzo Tamura; Elyse M Petrunak; Jeanne A Stuckey; Yanyan Han; Miao He; Duxin Sun; Hollis D Showalter; Nouri Neamati
Journal:  J Med Chem       Date:  2018-05-14       Impact factor: 7.446

Review 10.  Small molecule activators of the p53 response.

Authors:  Marcus J G W Ladds; Sonia Laín
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.